{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T13:54:14Z","timestamp":1781790854736,"version":"3.54.5"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["JAHA"],"published-print":{"date-parts":[[2026,6,2]]},"abstract":"<jats:sec xml:lang=\"en\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p xml:lang=\"en\">Long\u2010term efficacy and safety of mavacamten in Chinese patients with obstructive hypertrophic cardiomyopathy are unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p xml:lang=\"en\">Patients who completed the 30\u2010week, double\u2010blind, placebo\u2010controlled treatment period in EXPLORER\u2010CN (A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCM), with no active safety concerns, were eligible to enter the long\u2010term extension period to receive 48\u2010week mavacamten treatment. Patients previously on mavacamten continued mavacamten (dose at week 30; mavacamten\u2013mavacamten group); patients previously on placebo received mavacamten (starting dose, 2.5\u2009mg once daily; placebo\u2013mavacamten group). Key efficacy end points included change from baseline in echocardiographic measures, New York Heart Association functional class, 23\u2010item Kansas City Cardiomyopathy Questionnaire Clinical Summary Score, and cardiac biomarkers through week 78. Analyses were descriptive; no between\u2010group hypothesis testing was performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p xml:lang=\"en\">Seventy\u2010nine patients (mean age, 51.6\u2009years; 27.8% women) entered the long\u2010term extension period (mavacamten\u2013mavacamten, n=54; placebo\u2013mavacamten, n=25). In the mavacamten\u2013mavacamten group, numerical improvements in Valsalva and resting left ventricular outflow tract peak gradients were maintained through week 78 (mean change from baseline, \u221273.0\u2009mm\u2009Hg [95% CI, \u221286.4 to \u221259.5]; and \u221256.3\u2009mm\u2009Hg [95% CI, \u221267.1 to \u221245.5], respectively). Numerical improvements were also observed for other echocardiographic parameters, New York Heart Association class, Kansas City Cardiomyopathy Questionnaire Clinical Summary Score, and cardiac biomarkers through week 78. In the placebo\u2013mavacamten group, numerical improvements with mavacamten in these parameters were noted from week 30 to week 78. Long\u2010term mavacamten treatment appeared well tolerated; left ventricular ejection fraction &lt;50% was rare.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p xml:lang=\"en\">In this exploratory long\u2010term extension study, 78\u2010week mavacamten treatment appeared well\u2010tolerated and was associated with numerical improvements from baseline in echocardiographic parameters, New York Heart Association class, patient\u2010reported health status, and cardiac biomarkers in Chinese patients with obstructive hypertrophic cardiomyopathy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Registration<\/jats:title>\n                    <jats:p xml:lang=\"en\">\n                      URL:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrials.gov\">https:\/\/www.clinicaltrials.gov<\/jats:ext-link>\n                      ; Unique Identifier: NCT05174416.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1161\/jaha.125.046251","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T10:45:21Z","timestamp":1779705921000},"update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Long\u2010Term Efficacy and Safety of Mavacamten in Chinese Patients With Obstructive Hypertrophic Cardiomyopathy: Week 78 Results From the EXPLORER\u2010CN Study"],"prefix":"10.1161","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1140-4062","authenticated-orcid":false,"given":"Zhuang","family":"Tian","sequence":"first","affiliation":[{"name":"Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1304-6688","authenticated-orcid":false,"given":"Xiaoyan","family":"Li","sequence":"additional","affiliation":[{"name":"Renmin Hospital of Wuhan University, Hubei General Hospital","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8866-296X","authenticated-orcid":false,"given":"Liwen","family":"Li","sequence":"additional","affiliation":[{"name":"Southern Medical University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5652-4036","authenticated-orcid":false,"given":"Qing","family":"Zhang","sequence":"additional","affiliation":[{"name":"West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4583-3204","authenticated-orcid":false,"given":"Jian\u2019an","family":"Wang","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital of Zhejiang University School of Medicine","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunqi","family":"Shi","sequence":"additional","affiliation":[{"name":"The People\u2019s Hospital of Liaoning Province","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6171-4379","authenticated-orcid":false,"given":"Daoquan","family":"Peng","sequence":"additional","affiliation":[{"name":"The Second Xiangya Hospital of Central South University","place":["Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1305-3980","authenticated-orcid":false,"given":"Wei","family":"Ma","sequence":"additional","affiliation":[{"name":"Peking University First Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7960-6248","authenticated-orcid":false,"given":"Ping","family":"Yang","sequence":"additional","affiliation":[{"name":"China\u2010Japan Union Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6287-3128","authenticated-orcid":false,"given":"Xiang","family":"Cheng","sequence":"additional","affiliation":[{"name":"Huazhong University of Science and Technology","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2905-2109","authenticated-orcid":false,"given":"Wei","family":"Jin","sequence":"additional","affiliation":[{"name":"Ruijin Hospital, Shanghai Jiaotong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6674-5537","authenticated-orcid":false,"given":"Fang","family":"Wang","sequence":"additional","affiliation":[{"name":"Beijing Hospital, National Center of Gerontology and Institute of Geriatric Medicine, Chinese Academy of Medical Sciences","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimeng","family":"Xie","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Pan","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Florea","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb","place":["Princeton, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.117.311059"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.644682"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad194"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.120138"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-20042-9"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2024.101062"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021332"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2004.12.067"},{"key":"e_1_3_2_10_2","unstructured":"Bristol\u2010Myers Squibb Farmac\u00eautica LTDA . CAMZYOS\u00ae (mavacanteno). Brazilian bula professional. Accessed April 1 2025. https:\/\/www.bms.com\/assets\/bms\/brazil\/documents\/Camzyos_Bula_Profissional.pdf."},{"key":"e_1_3_2_11_2","unstructured":"Bristol\u2010Myers Squibb Canada . CAMZYOS\u2122 (mavacamten). Canadian product monograph. Accessed April 1 2025. https:\/\/www.bms.com\/assets\/bms\/ca\/documents\/productmonograph\/CAMZYOS_EN_PM.pdf."},{"key":"e_1_3_2_12_2","unstructured":"Bristol\u2010Myers Squibb Australia Pty Ltd . CAMZYOS\u00ae (mavacamten). Australian product information. Accessed April 1 2025. https:\/\/www.tga.gov.au\/sites\/default\/files\/2023\u201007\/auspar\u2010camzyos\u2010230703\u2010pi.pdf."},{"key":"e_1_3_2_13_2","unstructured":"Bristol\u2010Myers Squibb SA . CAMZYOS\u00ae (mavacamtenum). Professional information Swissmedic. Accessed April 1 2025. https:\/\/www.swissmedicinfo.ch\/ViewMonographie."},{"key":"e_1_3_2_14_2","unstructured":"Bristol Myers Squibb . CAMZYOS\u00ae (mavacamten). Korean prescribing information. Accessed April 1 2025. https:\/\/nedrug.mfds.go.kr\/searchDrug?sort=&sortOrder=false&searchYn=true&ExcelRowdata=&page=1&searchDivision=detail&itemName=&itemEngName=mavacamten&entpName=&entpEngName=&ingrName1=&ingrName2=&ingrName3=&ingrEngName=&itemSeq=&stdrCodeName=&atcCodeName=&indutyClassCode=&sClassNo=&narcoticKindCode=&cancelCode=&etcOtcCode=&makeMaterialGb=01&searchConEe=AND&eeDocData=&searchConUd=AND&udDocData=&searchConNb=AND&nbDocData=&startPermitDate=&endPermitDate=."},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001250"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31792-X"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00763-7"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2023.3030"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-24-0501"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae579"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2003.05.009"},{"key":"e_1_3_2_22_2","unstructured":"Bristol\u2010Myers Squibb China . The world's first cardiac myosin inhibitor Mavento\u00ae (mavaketyl capsules) was approved in China for the treatment of adults with obstructive hypertrophic cardiomyopathy. 2024."},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-071473"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.030607"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.124.072445"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40119-025-00409-5"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.crvasa.2015.02.003"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00345.2020"},{"key":"e_1_3_2_29_2","article-title":"Acute effects of a small\u2010molecule direct myosin\u2010attenuator (MYK\u2010581) in a mini\u2010pig genetic model of non\u2010obstructed hypertrophic cardiomyopathy: in\u00a0vivo evidence for contractile regulation with improved compliance and functional reserve","volume":"138","author":"del Rio CL","year":"2018","unstructured":"del Rio CL, Yadav A, Huang N, Geist GE, Ueyama Y, Youngblood BL, Evanchik MJ, Green EM, Divekar A, Ahmad F. Acute effects of a small\u2010molecule direct myosin\u2010attenuator (MYK\u2010581) in a mini\u2010pig genetic model of non\u2010obstructed hypertrophic cardiomyopathy: in\u00a0vivo evidence for contractile regulation with improved compliance and functional reserve. Circulation. 2018;138:abstract 13204.","journal-title":"Circulation"},{"key":"e_1_3_2_30_2","article-title":"In vivo cardiac effects of mavacamten (MYK\u2010461): evidence for negative inotropy and improved compliance","volume":"136","author":"del Rio CL","year":"2018","unstructured":"del Rio CL, Ueyama Y, Baker DC, Dalton SR, Lucats L, Janiak P, Olivier B, Lambing J, Evanchik MJ, Green EM. In vivo cardiac effects of mavacamten (MYK\u2010461): evidence for negative inotropy and improved compliance. Circulation. 2018;136:abstract 20593.","journal-title":"Circulation"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12574-020-00467-9"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/echo.14539"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/echo.13857"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.echo.2009.09.016"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31923-8"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1494"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.027618"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht070"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2023.09.028"}],"container-title":["Journal of the American Heart Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/JAHA.125.046251","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T13:25:48Z","timestamp":1781789148000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/JAHA.125.046251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":38,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,6,2]]}},"alternative-id":["10.1161\/JAHA.125.046251"],"URL":"https:\/\/doi.org\/10.1161\/jaha.125.046251","relation":{},"ISSN":["2047-9980"],"issn-type":[{"value":"2047-9980","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,2]]},"assertion":[{"value":"2025-09-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e046251"}}